# NeoTRIPaPDL1 (NCT02620280)

> Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: high-risk early or locally advanced triple-negative breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02620280
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Fondazione Michelangelo
- Conditions: Invasive Ductal Breast Carcinoma
- Interventions: Carboplatin; Abraxane; MPDL3280A; Surgery; Anthra
- Enrollment: 278
- Primary outcome: Event Free Survival (EFS)

## Indexed commentary on NeoTRIPaPDL1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=neotripapdl1-nct02620280

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02620280", "email": "<work email>"}; the inbox owner confirms by the emailed link.